Previous 10 | Next 10 |
2023-05-08 17:14:36 ET Zymeworks press release ( NASDAQ: ZYME ): Q1 GAAP EPS of -$0.37 beats by $0.12 . Revenue of $35.58M (+1762.8% Y/Y) beats by $16.06M . For further details see: Zymeworks GAAP EPS of -$0.37 beats by $0.12, revenue of $35.58M beats by ...
2023-05-08 16:12:40 ET Zymeworks press release ( NASDAQ: ZYME ): Q1 Non-GAAP EPS of -$0.34 beats by $0.20 . Revenue of $35.58M beats by $16.06M . Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at l...
Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, and potentially beyond Net quarterly loss decreased by 66% to $24.4 million as compared to first quarter in 2022 Presented 11 posters at the American Assoc...
2023-04-26 10:00:43 ET For further details see: Zymeworks, Jazz in pact over cancer antibody zanidatamab
● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles ● ZW171 induced potent preferential killing of cancer cells and potential to mitigate risk of on-target off-tumor to...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023. Following the announcement, management will host a confe...
2023-04-14 13:30:11 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch for a full list of events planned for the week or the Seeking Alpha earnings calendar for com...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Mr. Miller brings extensive commercial, corporate and business developmen...
2023-04-10 01:17:32 ET Summary Zymeworks has an enterprise value approaching zero, as milestone drug development payments were paid to the company in 2022. A significant pipeline, with partners helping to finance drug trials, is worthy of consideration. Numerous short sellers ...
2023-03-21 11:18:17 ET Wells Fargo said that Zymeworks ( NASDAQ: ZYME ) is a buy citing the biotech's potential royalty streams and milestones from its lead oncology candidate. The firm has a $12 price target (~41% upside based on Monday's close). Derek Archila wrote t...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...